

X	VASCULAR OCCLUSION IN NON-HUMAN PRIMATES" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS" 2003, PP 855-881, vol. 304, THE AMERICAN SOCIETY OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS.
DL	CHESEBRO ET AL, "ANTITHROMBOTIC THERAPY AND PROGRESSION OF CORONARY ARTERY DISEASE, ANTIPLATELET VS. ANTITHROMBINS", CIRCULATION, 1992, 86[suppl III]: III-100-III-111]
DL	WHITE, HARVEY, "NEWER ANTIPLATELET AGENTS IN ACUTE CORONARY SYNDROMES" CARDIOLOGY DEPT. GREEN LANE HOSPITAL, NEW ZEALAND, e-mail: harveyw@ahsl.co.nz, 1999, MOSBY, INC..
DL	VERSTRAETE ET AL, "NOVEL ANTITHROMBOTIC DRUGS IN DEVELOPMENT" , CENTER FOR MOLECULAR AND VASCULAR BIOLOGY, UNIVERSITY OF LEUVEN, BELGIUM, DRUGS, 1995, pp 856-884, Adis International Limited.
DL	WEKSLER, BABETTE, "ANTIPLATELET AGENTS IN STROKE PREVENTION" DEPT. OF MEDICINE, NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDICAL CENTER, NEW YORK, NY USA, 2000; 10(suppl 5) 41-48, www.karger.com/journals/ced.
X	MOUSA, SHAKER, "ANTIPLATELET THERAPIES: FROM ASPIRIN TO GPIIb/IIIa-RECEPTOR ANTAGONISTS AND BEYOND" THERAPEUTIC FOCUS, ELSEVIER SCIENCE LTD, 1999, PP 552-560, vol. 4, No. 12, USA.

Examiner Signature	Date Considered
-----------------------	--------------------

David Ruben

4-18-06